Our Tablet Range by Therapeutic Segment

We don't manufacture a generic "tablet range" — our portfolio is built across the categories that move fastest in Indian PCD markets:

• Antibiotics & Anti-infectives: Cefpodoxime Proxetil dispersible tablets (CFXOTIL-100 DT), Ofloxacin combinations (LXQUINO-200, LXQUINO-OZ with Ornidazole), Azithromycin (AZUSTAN-250 / AZUSTAN-500), Amoxicillin ranges (AMEXOSYN-375, -625, -1GM, and a paediatric AMEXOSYN-KID variant), and Faropenem (AFNOBACT-200) for resistant infections.
• Pain Management & Anti-inflammatory: Nimesulide + Paracetamol combinations (KIKNIM-P), Aceclofenac-based formulations in multiple combinations — with Paracetamol & Chlorzoxazone (LXFEN-MR), with Thiocolchicoside (LXFEN-TH) — and our Etoricoxib range (LXTRIB 90mg, 120mg, plus combination variants with Pregabalin and Thiocolchicoside).
• Gastro & Digestive Health: Pantoprazole 40mg (QUSOPAN-40) and Ursodeoxycholic Acid (LXURSE-150) for hepatobiliary conditions.
• Antifungal: Fluconazole in both 150mg and 200mg strengths (LXCON series).
• ENT & Vertigo: Betahistine Dihydrochloride in 8mg and 16mg strengths (HISTOVER).
• Steroidal Anti-inflammatory: Deflazacort 6mg (LXZAR-6).
• Cold, Cough & Allergy: Combination formulations with Paracetamol, Phenylephrine, Diphenhydramine, and Caffeine (LXWAR series).

View the complete tablet product list with pack sizes →

Manufacturing & Quality Standards

Our tablets are manufactured at our Baddi (Himachal Pradesh) facility under stringent WHO-GMP guidelines. Every batch goes through:

• Raw material testing before production begins.
• In-process quality checks at defined manufacturing stages.
• Finished product testing against DCGI-approved specifications.
• Stability testing for shelf-life validation.

The facility holds ISO certification alongside WHO-GMP status, and all formulations require explicit DCGI approval before they're released to our franchise partners.

What You Get as a Tablet Franchise Partner

• Exclusive Monopoly Rights: One franchise partner per district. No internal competition on our brands in your area.
• Alu-Alu Premium Packaging: Standard across the tablet range, not an expensive add-on.
• Full Promotional Kit: Visual aids, MR bags, product cards, and sample kits included.
• PAN-India Delivery: A robust supply chain covering all 28 states.
• Drug Licence Guidance: Our team walks you through the DL application process if you don't already hold one.

Market Opportunity for Tablet PCD Pharma Franchise in India

India's pharmaceutical industry ranks third globally by volume, with over 3,000 companies operating across roughly 10,500 manufacturing units. As of 2026, the domestic market is valued at approximately $60 billion and is projected to reach $130 billion by 2030, growing at a CAGR of over 10% (Economic Survey 2025–26, Government of India). Tablets remain the largest dosage-form segment in this market, which is why we've built our widest product range in this specific category.

Frequently Asked Questions

Start Your Tablets PCD Franchise Today

Partner with Lxir Medilabs to secure your exclusive territory and premium product range.

• Phone: +91-98759-13317 / +91-99888-89031
• Email: sales@lxir.in
• Address: SCO-48, Swastik Vihar, MDC Sector-5, Panchkula (HR)
• Manufacturing: Baddi, Himachal Pradesh